RSUME inhibits VHL and regulates its tumor suppressor function

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Von Hippel-Lindau (VHL) disease is characterized by tumor formation due to mutations or loss of the pVHL protein.
• Mutated pVHL leads to a constitutively active Hypoxia Inducible Factor (HIF), promoting tumor growth.
• The precise mechanisms regulating the pVHL-HIF pathway remain incompletely understood.

Purpose of the Study:

• To elucidate the molecular mechanism by which RSUME stabilizes HIFs.
• To investigate the effect of RSUME on pVHL function.
• To determine the role of RSUME in pVHL-related tumor progression.

Main Methods:

• Investigated RSUME's interaction with pVHL using sumoylation and co-immunoprecipitation assays.
• Assessed the impact of RSUME on the pVHL-Elongin-Cullin (ECV) complex assembly and HIF ubiquitination/degradation.
• Utilized a reporter assay to evaluate RSUME's role in pVHL mutant function.
• Confirmed findings in human VHL tumors and a mouse xenograft model.

Main Results:

• RSUME directly sumoylates and interacts with pVHL, inhibiting ECV complex formation.
• RSUME hinders the ubiquitination and degradation of HIF-1α and HIF-2α.
• RSUME is essential for the loss-of-function of type 2 pVHL mutants in VHL tumors.
• Knockdown of RSUME impaired tumor growth, HIF-2α expression, and vascularization in a mouse model.

Conclusions:

• RSUME stabilizes HIFs by negatively regulating pVHL activity, promoting VHL-related tumor progression.
• RSUME represents a novel molecular factor and potential therapeutic target for VHL-related pathologies.
• This study reveals a new regulatory mechanism within the pVHL/HIF pathway crucial for tumor development.